Get the Stockscreener App
14.29
2.95%
0.41
Pre-market:
14.50
0.21
+1.47%
Zymeworks Inc. stock is traded at $14.29, with a volume of 274.61K.
It is up +2.95% in the last 24 hours and up +1.06% over the past month.
Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidate is ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer. It is also developing ZW49, a bispecific antibody-drug conjugate that is in IND application stage. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Celgene Corporation and Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; and Janssen Biotech, Inc., as well as a collaboration agreement with Celgene Corporation. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies targeting cytokine-receptor pathways. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
See More
Previous Close:
$13.88
Open:
$14.09
24h Volume:
274.61K
Relative Volume:
0.56
Market Cap:
$984.26M
Revenue:
$62.71M
Net Income/Loss:
$-112.51M
P/E Ratio:
-9.4636
EPS:
-1.51
Net Cash Flow:
$-96.01M
1W Performance:
+4.92%
1M Performance:
+1.06%
6M Performance:
+46.11%
1Y Performance:
+44.64%
1-Day Range:
$13.88
$14.38
1-Week Range:
$13.58
$14.63
52-Week Range:
$7.97
$17.70
Zymeworks Inc. Stock (ZYME) Company Profile
Name
Zymeworks Inc.
Sector
Industry
Phone
604-678-1388
Address
1385 West 8th Avenue, Suite 540, Vancouver, BC
Compare ZYME with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
14.29 | 984.26M | 62.71M | -112.51M | -96.01M | -1.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-07-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-01-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-21-23 | Resumed | Wells Fargo | Overweight |
| Jan-04-23 | Reiterated | H.C. Wainwright | Neutral |
| Dec-20-22 | Upgrade | Jefferies | Hold → Buy |
| Nov-01-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-21-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-04-22 | Resumed | Wells Fargo | Overweight |
| May-05-22 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-15-22 | Initiated | Evercore ISI | Outperform |
| Dec-10-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Nov-17-21 | Resumed | Guggenheim | Neutral |
| Oct-07-21 | Initiated | Jefferies | Hold |
| Mar-31-21 | Initiated | Credit Suisse | Outperform |
| Feb-25-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-08-21 | Resumed | H.C. Wainwright | Buy |
| Jan-25-21 | Downgrade | Citigroup | Buy → Neutral |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Aug-06-20 | Initiated | SVB Leerink | Outperform |
| Jan-10-20 | Initiated | Wolfe Research | Outperform |
| Dec-09-19 | Initiated | JP Morgan | Neutral |
| Nov-25-19 | Initiated | H.C. Wainwright | Buy |
| Nov-20-19 | Initiated | Guggenheim | Buy |
| Sep-30-19 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-30-19 | Initiated | Stifel | Buy |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| May-11-18 | Upgrade | Barclays | Underweight → Equal Weight |
| Mar-19-18 | Initiated | Raymond James | Outperform |
View All
Zymeworks Inc. Stock (ZYME) Latest News
EcoR1 Capital, LLC Expands Stake in Zymeworks Inc with Strategic Acquisition - GuruFocus.com
Assenagon Asset Management S.A. Boosts Stake in Zymeworks Inc. (NYSE:ZYME) - MarketBeat
Engineered Multispecific Antibodies Innovation Research Report 2024: Patent Trends Show a Noticeable Surge in 2023 with Regeneron, Roche, and Amgen Emerging as the Top Patent Filers - GlobeNewswire Inc.
Opinion: Four trends to watch in B.C.'s tech sector - Business in Vancouver
Zymeworks (NYSE:ZYME) Shares Gap Up on Insider Buying Activity - MarketBeat
EcoR1 Capital, LLC Increases Stake in Zymeworks Inc - GuruFocus.com
ZYME (Zymeworks) Total Stockholders Equity : $366.98 Mil (As of Sep. 2024) - GuruFocus.com
Insider Buying: Zymeworks Inc. (NYSE:ZYME) Director Acquires 74,125 Shares of Stock - MarketBeat
Ecor1 capital acquires $2.28 million in Zymeworks stock By Investing.com - Investing.com Nigeria
Ecor1 Capital, Llc Buys 39,029 Shares of Zymeworks Inc. (NYSE:ZYME) Stock - MarketBeat
Ecor1 capital acquires $2.28 million in Zymeworks stock - Investing.com
Zymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc Acquires 204,098 Shares of Stock - MarketBeat
Ecor1 Capital, Llc Purchases 21,021 Shares of Zymeworks Inc. (NYSE:ZYME) Stock - MarketBeat
Ecor1 capital increases stake in Zymeworks with $2.97 million purchase By Investing.com - Investing.com South Africa
Ecor1 capital increases stake in Zymeworks with $2.97 million purchase - Investing.com
Zymeworks in Focus for Insider Activity: Catalysts Ahead - Benzinga
Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026 - The Korea Bizwire
Zymeworks Sets Strategic Milestones for 2025-2026 with Focus on Novel Therapeutics - TipRanks
Zymeworks says it has enough cash to operate through H2 2027 - Seeking Alpha
Zymeworks Unveils 2025 Pipeline Strategy: Multiple INDs Planned, $324M Cash Position Supports Growth - StockTitan
Wall Street Analysts Believe Zymeworks (ZYME) Could Rally 41.36%: Here's is How to Trade - Yahoo Finance
Zymeworks CEO Kenneth Galbraith sells $855,016 in stock By Investing.com - Investing.com Australia
Zymeworks chief scientific officer sells shares worth $316,390 By Investing.com - Investing.com Australia
Zymeworks Inc. (NYSE:ZYME) CEO Sells $854,781.72 in Stock - MarketBeat
Insider Selling: Zymeworks Inc. (NYSE:ZYME) EVP Sells 11,110 Shares of Stock - MarketBeat
Paul Andrew Moore Sells 21,200 Shares of Zymeworks Inc. (NYSE:ZYME) Stock - MarketBeat
Zymeworks chief scientific officer sells shares worth $316,390 - Investing.com
Zymeworks CEO Kenneth Galbraith sells $855,016 in stock - Investing.com
Zymeworks (NYSE:ZYME) Shares Gap Up After Insider Buying Activity - Defense World
Zymeworks (NYSE:ZYME) Shares Gap Up Following Insider Buying Activity - MarketBeat
Ecor1 Capital, Llc Buys 157,880 Shares of Zymeworks Inc. (NYSE:ZYME) Stock - MarketBeat
Zymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc Buys 58,988 Shares - MarketBeat
Geode Capital Management LLC Grows Stock Position in Zymeworks Inc. (NYSE:ZYME) - Defense World
Zymeworks Inc. (NYSE:ZYME) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Insider Buying: Zymeworks Inc. (NYSE:ZYME) Director Purchases 11,958 Shares of Stock - MarketBeat
Zymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc Purchases 16,692 Shares - MarketBeat
Ecor1 capital increases stake in Zymeworks with $1.88 million purchase By Investing.com - Investing.com Canada
Ecor1 capital increases stake in Zymeworks with $1.88 million purchase - Investing.com India
Zymeworks Inc. (NYSE:ZYME) Shares Acquired by Barclays PLC - MarketBeat
Zymeworks Inc. (NYSE:ZYME) Shares Bought by State Street Corp - MarketBeat
Zymeworks (NYSE:ZYME) Shares Down 2.4%Here's Why - MarketBeat
Y Intercept Hong Kong Ltd Has $147,000 Stock Holdings in Zymeworks Inc. (NYSE:ZYME) - MarketBeat
Zymeworks Inc. Stock (ZYME) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):